Printer Friendly

Angiomax Will Retain Decision Resources' Proprietary Clinical Gold Standard Status Over Current and New Therapies, Including Recently-Approved Efient, for the Treatment of NSTEMI.

Angiomax Will Remain the NSTEMI Market Share Leader Through 2017, According to a New Report from Decision Resources

WALTHAM, Mass., Feb. 25 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a therapy's effect on incidence of mortality at 30 days is the attribute that most influences surveyed cardiologists' prescribing decisions in non-ST elevation myocardial infarction (NSTEMI). Data and the opinions of interviewed thought leaders indicate that current and emerging drugs, including Eli Lilly/Daiichi Sankyo's Efient, have no advantage in this attribute over The Medicines Company's Angiomax, the market sales leading agent.

The new report entitled NSTEMI: Finding the Balance between Efficacy and Safety finds that a drug that reduces mortality more than Angiomax at 30 days with significantly lower rates of bleeding would earn a 50 percent patient share in the United States and a 60 percent patient share in Europe, according to surveyed U.S. and European cardiologists. Angiomax, which was Decision Resources' proprietary clinical gold standard in 2008 for NSTEMI, will remain the clinical gold standard therapy and the market share leader through 2017, due to its efficacy and safety

The report finds that although some therapies in development for NSTEMI hold promise, most have either efficacy or safety and tolerability features that surveyed cardiologists rated inferior when compared with Angiomax. New agents in the market include Efient, which was approved by the European Medicines Agency in February 2009 for treatment of NSTEMI in the European Union.

"Angiomax has the most robust clinical data of drugs in its class for its use in NSTEMI and benefits from an immediate onset of action, which has driven physician usage and has enabled it to dominate the NSTEMI market," said Decision Resources Analyst Amir Mobasheri. "However, Efient and other emerging drugs such as AstraZeneca's ticagrelor, The Medicines Company's cangrelor and GlaxoSmithKline's Arixtra are not expected to achieve a market share as high as that of Angiomax, largely owing to safety or efficacy concerns."

About the Report

NSTEMI: Finding the Balance between Efficacy and Safety is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (http://www.decisionresources.com/) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.decisionresourcesinc.com/.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
 For more information, contact:

 Decision Resources Decision Resources, Inc.
 Christopher Comfort Elizabeth Marshall
 781-296-2597 781-296-2563
 ccomfort@dresources.com emarshall@dresources.com



CONTACT: Christopher Comfort of Decision Resources, +1-781-296-2597, ccomfort@dresources.com; Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563, emarshall@dresources.com

Web Site: http://www.decisionresources.com/
COPYRIGHT 2009 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 25, 2009
Words:558
Previous Article:Marriott Nearly Doubles Billion Dollar Spending Goal With Diverse Suppliers.
Next Article:Seven Summits Research Releases Comments on MSFT, HIG, SPWRA, AGU, and TOL.
Topics:


Related Articles
Increase in Diagnosed Events and Revascularization Procedures will Drive Market Growth in the Treatment of Acute Coronary Syndrome.
Neurochem's New Agent Will Become the Clinical Gold Standard for the Treatment of Alzheimer's Disease in 2008.
Launch of Drugs from Medarex/Bristol-Myers Squibb and Pfizer Will Significantly Impact the Market for Treatment of Malignant Melanoma.
A Drug With Efficacy Superior to That of Remicade at Inducing Closure and Healing of Fistulas Would Earn a 30 Percent Patient Share in the Crohn's...
Robust Sales of Integrilin, ReoPro and Aggrastat Will Drive the Unstable Angina/Non-ST-Elevation Myocardial Infarction Drug Market.
Surveyed Gastroenterologists Indicate That Humira Has Advantages Over Remicade in Maintaining Clinical Remission of Crohn's Disease.
A First-Line Therapy for Renal Cell Carcinoma that can Increase Overall Survival when Compared with Sutent Would Earn a Higher Patient Share in the...
Surveyed Oncologists Indicate that Avastin has Advantages over Temodar/Temodal in Increasing Overall Survival of High-Grade Glioma.
For ST-Elevation Myocardial Infarction (STEMI), Interviewed Experts Indicate That The Medicines Company's Angiomax/Angiox Has Efficacy Advantages...
A Fibromyalgia Drug That Improves Sleep Quality More Than Pfizer's Lyrica Would Earn Sizeable Patient Share in the U.S. and Europe; Lyrica Will...

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters